Nguyen, Hao Trong http://orcid.org/0000-0002-7732-0497
Vu, Anh Tuan
Pham, Nhi Thi Uyen http://orcid.org/0000-0002-3976-9963
Tran, Tu Nguyen Anh http://orcid.org/0000-0003-1111-9659
Pham, Nguyen Nhat http://orcid.org/0000-0003-2176-0941
Bui, Huong Thi Thanh
Pham, Thuyen Thi
Dinh, Vi Thi Thuy
Bui, Yen Thi
Vu, Thao Thi Phuong http://orcid.org/0000-0003-3946-6820
Funding for this research was provided by:
The study was funded by Novartis Vietnam Co., Ltd and the hospitals are the regulatory sponsors.
Article History
Received: 31 August 2023
Accepted: 23 October 2023
First Online: 17 November 2023
Declarations
:
: Hao Trong Nguyen has served as an advisory board member and speaker for Novartis, Janssen, and Menarini. Nhi Thi Uyen Pham, Tu Nguyen Anh Tran, and Thao Thi Phuong Vu have served as a speaker for Novartis, Janssen, and Menarini. Huong Thi Thanh Bui, Vi Thi Thuy Dinh have served as a speaker for Novartis. Huong Thi Thanh Bui, Vi Thi Thuy Dinh have served as a speaker for Novartis. Yen Thi Bui was an employee of Novartis Vietnam Co., Ltd at the time of manuscript development. Anh Tuan Vu, Nguyen Nhat Pham, and Thuyen Thi Pham have nothing to disclose.
: This study has been reviewed and approved by the Institutional Review Board/Independent Ethics Committee of Ho Chi Minh City Hospital of Dermato-Venereology and Quy Hoa National Leprosy Dermatology Hospital. Informed consent was waived due to the retrospective nature of the study.